Objective: Schizophrenia, a common neurological disorder appearing in the late teens or early adulthood, is characterized by disorganized thinking, behaviour, and perception of emotions. Aberrant N-methyl-D-aspartate (NMDA) receptor-mediated synaptic plasticity is a major pathological event here due to dysfunction of dopamine and glutamate transmission at NMDA receptors. De-regulated brain-derived neurotrophic factor (BDNF), i.e., its signalling through the tropomyosin receptor kinase B (TrkB) receptor, is a major feature of schizophrenia. With recent global awareness of traditional plant medicines in reducing side effects, the aim of our study was to evaluate the efficacy of the ethanolic root extract of a herb belonging to the Valerianacea family, Nardostachys jatamansi, against ketamine-induced schizophrenia-like model in rats.
Methods: The effect of the N. jatamansi drug (oral dosage of 500 mg/kg body weight for 14 days) in ketamine-administered male Wistar albino rats (30 mg/kg body weight for 5 days) on modulating behaviour and the level of neurotransmitters like dopamine and glutamate was studied in whole-brain homogenates, and its influence on BDNF and TrkB levels in 2 relevant brain regions, the hippocampus and prefrontal cortex, was assessed.
Results: We observed that N. jatamansi treatment exhibited encouraging results in the modulation of ketamine-induced schizophrenia-like behaviours, principally the positive symptoms. Our drug both significantly upregulated the glutamate level and downregulated the dopamine level in whole-brain homogenates and retained the normal levels of BDNF (in the hippocampus but not in the prefrontal cortex) and TrkB (in both hippocampus and prefrontal cortex) induced by ketamine in rats.
Conclusion: These findings suggest a neuroprotective effect of the ethanolic root extract of N. jatamansi against ketamine-induced schizophrenia-like symptoms in rats; possibly, regarding its effect on TrkB signalling. Further research is warranted in the treatment of schizophrenic symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000454985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The amino acid metabolism pathway of peripheral T lymphocytes and ketamine-induced schizophrenia-like phenotype.
J Psychiatry Neurosci
December 2024
West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China
Article Synopsis
- - The study investigates how changes in peripheral adaptive immune cells affect metabolic profiles in a ketamine-treated mouse model of schizophrenia, suggesting a link between immune responses and mental health issues.
- - Using flow cytometry and advanced metabolomics techniques, researchers found an increase in CD3 T cells and notable alterations in amino acid metabolism, particularly elevated levels of glycine, alanine, asparagine, and aspartic acid.
- - Although the research highlights the role of peripheral amino acid metabolism in ketamine-induced schizophrenia symptoms, it has yet to pinpoint the specific metabolic pathways responsible for these changes.
Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.
J Psychiatr Res
November 2024
DELSU Joint Canada-Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.
Background: Neurochemical dysregulations resulting from N-methyl-D-aspartate hypofunction (NMDA), are exacerbated by neuroimmune and oxidative stress and are known risk factors for neuropsychiatric disorders like schizophrenia-like diseases. Here, we investigate the protective and curative effects, and mechanisms of silymarin, a polyphenolic flavonoid with neuroprotective functions in preventive-reversal model of ketamine, an NMDA antagonist in mice.
Methods: Mice were grouped into 6 cohorts (n = 9).
Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
Neuropsychopharmacology
December 2024
Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece.
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been linked to antipsychotic effects with unclear mechanistic basis.
View Article and Find Full Text PDFExploring the interplay of chronic toxoplasmosis and NMDAR dysfunction: Insights into schizophrenia-like behaviors and therapeutic potential.
Open Vet J
July 2024
Department of Veterinary Parasitology, Karaj Branch, Islamic Azad University, Karaj, Iran.
Article Synopsis
- * The study analyzed different groups of mice, including those infected with toxoplasmosis and those induced with schizophrenia-like symptoms through ketamine, observing their behavior and brain changes.
- * Results showed that both toxoplasmosis and ketamine decreased antioxidant levels and altered NMDAR expression, indicating potential targets for future therapies aimed at cognitive and neurological impairments related to these conditions.
Understanding the role of early life stress and schizophrenia on anxiety and depressive like outcomes: An experimental study.
Behav Brain Res
July 2024
Department of Human Physiology, Faculty of Health Sciences North West University, Potchefstroom campus, 11 Hoffman St., Potchefstroom 2531, South Africa.
Background: Adverse experiences due to early life stress (ELS) or parental psychopathology such as schizophrenia (SZ) have a significant implication on individual susceptibility to psychiatric disorders in the future. However, it is not fully understood how ELS affects social-associated behaviors as well as the developing prefrontal cortex (PFC).
Objective: The aim of this study was to investigate the impact of ELS and ketamine induced schizophrenia like symptoms (KSZ) on anhedonia, social behavior and anxiety-like behavior.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!